AstraZeneca said the expansion supports its ambition to reach $80 billion in annual revenue by 2030, with half coming from the US ...

AstraZeneca plans to invest $50B in its U.S. footprint by 2030. Some of that will be directed to a new GLP-1 manufacturing facility in Virginia.

The MC4R agonist targets rare genetic and hypothalamic obesity, with potential as a combination or maintenance therapy for general obesity alongside GLP-1 agents.

The lawsuit said the union’s health plan allowed coverage of Xenical to treat obesity but not newer products such as Wegovy ...

Some people are discovering that being thinner can sometimes mean looking older. Local cosmetic surgeons weigh-in with ...

New research from experts at the University of Virginia (UVA) says that GLP-1 drugs may help people lose weight, but do not ...

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a ...

Experts reveal how Mounjaro actually works on your body after people took to social media complaining over 'hair loss' side ...

The world of prior authorization, and the hoops we need to jump through, has gotten just more and more ridiculous, bordering ...

More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...

In today's Morning Rounds newsletter: a failed long Covid drug may get another shot, the benefits of even a little activity ...

West Pharmaceutical Services Inc. (NYSE: WST) is one of the most oversold S&P 500 stocks so far in 2025. On June 24, Barclays ...